 Ganesh Narayanasamy
Concepts (121)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy Planning, Computer-Assisted | 22 | 2023 | 248 | 4.670 |
Why?
| | Radiotherapy, Intensity-Modulated | 17 | 2023 | 172 | 3.240 |
Why?
| | Radiosurgery | 11 | 2023 | 118 | 3.230 |
Why?
| | Radiotherapy Dosage | 21 | 2023 | 244 | 1.730 |
Why?
| | Phantoms, Imaging | 6 | 2022 | 121 | 1.610 |
Why?
| | Particle Accelerators | 6 | 2022 | 50 | 1.520 |
Why?
| | Radiometry | 9 | 2022 | 123 | 1.510 |
Why?
| | Organs at Risk | 7 | 2023 | 69 | 1.220 |
Why?
| | Electrons | 3 | 2016 | 19 | 1.110 |
Why?
| | Quality Assurance, Health Care | 4 | 2020 | 149 | 1.040 |
Why?
| | Lung Neoplasms | 7 | 2023 | 606 | 0.990 |
Why?
| | Neoplasms | 5 | 2020 | 1235 | 0.980 |
Why?
| | Imaging, Three-Dimensional | 3 | 2009 | 151 | 0.860 |
Why?
| | Prostatic Neoplasms | 4 | 2022 | 394 | 0.810 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 268 | 0.780 |
Why?
| | Brain Neoplasms | 2 | 2016 | 287 | 0.780 |
Why?
| | Gamma Rays | 3 | 2020 | 49 | 0.740 |
Why?
| | Tumor Burden | 3 | 2016 | 132 | 0.710 |
Why?
| | Xerostomia | 1 | 2019 | 3 | 0.690 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2019 | 21 | 0.680 |
Why?
| | Photons | 2 | 2016 | 18 | 0.670 |
Why?
| | Radiotherapy, Conformal | 3 | 2019 | 53 | 0.670 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 40 | 0.660 |
Why?
| | Radiation Dosage | 3 | 2016 | 157 | 0.660 |
Why?
| | Deglutition Disorders | 1 | 2019 | 77 | 0.630 |
Why?
| | Ultrasonography, Mammary | 2 | 2009 | 60 | 0.610 |
Why?
| | Models, Biological | 2 | 2020 | 727 | 0.590 |
Why?
| | Radiation Protection | 2 | 2016 | 47 | 0.560 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 449 | 0.550 |
Why?
| | Equipment Contamination | 1 | 2016 | 18 | 0.550 |
Why?
| | Radiation Tolerance | 1 | 2017 | 85 | 0.540 |
Why?
| | Lung | 4 | 2023 | 486 | 0.520 |
Why?
| | Whole-Body Irradiation | 1 | 2016 | 131 | 0.510 |
Why?
| | Software | 2 | 2015 | 273 | 0.500 |
Why?
| | Algorithms | 5 | 2017 | 615 | 0.440 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2017 | 242 | 0.440 |
Why?
| | Humans | 32 | 2023 | 49974 | 0.430 |
Why?
| | Monte Carlo Method | 3 | 2021 | 84 | 0.370 |
Why?
| | Ultrasonography, Doppler, Color | 2 | 2007 | 33 | 0.360 |
Why?
| | Breast Neoplasms | 3 | 2016 | 1174 | 0.350 |
Why?
| | Biometry | 1 | 2007 | 21 | 0.300 |
Why?
| | Fingers | 1 | 2007 | 32 | 0.300 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2007 | 106 | 0.280 |
Why?
| | Brain | 1 | 2013 | 1328 | 0.250 |
Why?
| | Models, Theoretical | 2 | 2016 | 175 | 0.250 |
Why?
| | Radiation Oncology | 1 | 2022 | 23 | 0.210 |
Why?
| | Scattering, Radiation | 3 | 2016 | 31 | 0.200 |
Why?
| | Arteriovenous Malformations | 1 | 2022 | 67 | 0.190 |
Why?
| | Probability | 2 | 2022 | 164 | 0.190 |
Why?
| | Weightlessness Simulation | 1 | 2020 | 19 | 0.180 |
Why?
| | Thymus Gland | 1 | 2020 | 42 | 0.180 |
Why?
| | Neoplasms, Experimental | 1 | 2020 | 114 | 0.180 |
Why?
| | Radiotherapy | 1 | 2020 | 128 | 0.170 |
Why?
| | Spleen | 1 | 2020 | 172 | 0.170 |
Why?
| | India | 1 | 2019 | 51 | 0.170 |
Why?
| | Reproducibility of Results | 2 | 2015 | 1193 | 0.160 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 154 | 0.160 |
Why?
| | Immunotherapy | 1 | 2020 | 238 | 0.160 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 16 | 0.160 |
Why?
| | Male | 9 | 2022 | 25241 | 0.160 |
Why?
| | Equipment Design | 2 | 2016 | 284 | 0.150 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2018 | 27 | 0.150 |
Why?
| | Retrospective Studies | 5 | 2023 | 6108 | 0.150 |
Why?
| | Breast | 2 | 2009 | 85 | 0.150 |
Why?
| | Tomography, Spiral Computed | 1 | 2017 | 56 | 0.140 |
Why?
| | Thermoluminescent Dosimetry | 1 | 2016 | 7 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2018 | 1171 | 0.140 |
Why?
| | Incidence | 1 | 2019 | 1003 | 0.130 |
Why?
| | Plant Extracts | 1 | 2018 | 190 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 2 | 2022 | 1159 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2019 | 326 | 0.130 |
Why?
| | Female | 7 | 2020 | 26472 | 0.120 |
Why?
| | Prognosis | 1 | 2019 | 1942 | 0.120 |
Why?
| | Follow-Up Studies | 1 | 2019 | 2182 | 0.120 |
Why?
| | Middle Aged | 3 | 2019 | 12069 | 0.120 |
Why?
| | Quality Control | 1 | 2014 | 94 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 861 | 0.110 |
Why?
| | X-Rays | 2 | 2023 | 55 | 0.090 |
Why?
| | Information Theory | 1 | 2009 | 3 | 0.090 |
Why?
| | Automation | 1 | 2009 | 17 | 0.090 |
Why?
| | Ultrasonography, Doppler | 1 | 2009 | 42 | 0.090 |
Why?
| | Regional Blood Flow | 1 | 2009 | 108 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 1537 | 0.080 |
Why?
| | Organ Size | 1 | 2009 | 226 | 0.080 |
Why?
| | Blood Vessels | 1 | 2009 | 72 | 0.080 |
Why?
| | Adult | 2 | 2019 | 13236 | 0.080 |
Why?
| | Aged | 1 | 2019 | 9310 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2020 | 1403 | 0.060 |
Why?
| | Mice | 3 | 2020 | 5739 | 0.060 |
Why?
| | United States | 1 | 2015 | 4860 | 0.060 |
Why?
| | Animals | 4 | 2020 | 13187 | 0.060 |
Why?
| | Time Factors | 1 | 2009 | 2903 | 0.050 |
Why?
| | Urinary Bladder | 1 | 2022 | 92 | 0.050 |
Why?
| | Rectum | 1 | 2022 | 54 | 0.050 |
Why?
| | Catecholamines | 1 | 2020 | 46 | 0.050 |
Why?
| | Drinking | 1 | 2020 | 38 | 0.050 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 184 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 304 | 0.040 |
Why?
| | Energy Intake | 1 | 2020 | 170 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2020 | 170 | 0.040 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2018 | 7 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 637 | 0.040 |
Why?
| | Cyclin D1 | 1 | 2018 | 56 | 0.040 |
Why?
| | Body Weight | 1 | 2020 | 513 | 0.040 |
Why?
| | Parotid Gland | 1 | 2018 | 9 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2018 | 106 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 56 | 0.040 |
Why?
| | Uncertainty | 1 | 2018 | 45 | 0.040 |
Why?
| | Poisson Distribution | 1 | 2017 | 34 | 0.040 |
Why?
| | Radiobiology | 1 | 2017 | 21 | 0.040 |
Why?
| | Esophagus | 1 | 2018 | 84 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2016 | 23 | 0.030 |
Why?
| | Cell Survival | 1 | 2018 | 600 | 0.030 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2016 | 33 | 0.030 |
Why?
| | Filtration | 1 | 2016 | 24 | 0.030 |
Why?
| | Calibration | 1 | 2016 | 58 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2020 | 1455 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2020 | 1816 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2018 | 1007 | 0.030 |
Why?
| | Liver | 1 | 2019 | 1115 | 0.030 |
Why?
| | Rats | 1 | 2016 | 3305 | 0.020 |
Why?
|
|
Narayanasamy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|